Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne.

Diane M ThiboutotNoah CraftRobert RissmannEwa GatlikMalika SouquièresJulie JonesChristian Loesche

Published in: The Journal of dermatological treatment (2022)

Anti-IL-17A therapy was not significantly different compared to the placebo in reducing inflammatory lesions in patients with moderate to severe acne.

Keyphrases

placebo controlled
double blind
high intensity
early onset
oxidative stress
hidradenitis suppurativa
phase iii
drug induced
stem cells
study protocol
squamous cell carcinoma
radiation therapy
mesenchymal stem cells
rectal cancer